Ariane Rezvilutamide Application Scope

Ariane is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) who present with a high tumour burden.

Ariane Rezvilutamide Characteristics

Ingredients: Rezvilutamide
Properties: Second-generation androgen receptor (AR) inhibitors, while exhibiting high AR inhibitory activity, demonstrate significantly reduced blood-brain barrier permeability compared to existing products in the same class, thereby lowering the risk of central nervous system toxicity.
Packaging Specification: 80 mg per tablet
Storage: Store at room temperature
Expiry Date: See outer packaging
Executive Standard: See the approved package insert
Approval Number: H20220016
Date of Revision: See the latest approved package insert
Manufacturer: Jiangsu Hengrui Medicine Co., Ltd.

Guidelines for the Use of Ariane

Dosage and Administration:
- Recommended Dose: The recommended dose is 240mg (3 tablets) once daily.
- Administration: Take orally, swallowing the tablet whole. May be taken with or without food. Patients should also undergo androgen deprivation therapy (ADT), either concurrently with gonadotropin-releasing hormone analogue (GnRHa) treatment or following bilateral orchiectomy.
- Missed Dose: If a dose is missed on the day, take it as soon as possible. If an entire day’s dose is missed, continue with the normal dose the following day without doubling the dose.
Adverse Reactions:
- Common Adverse Reactions: Fatigue, rash, itching, hypertriglyceridaemia, hypercholesterolaemia, etc.
- Serious Adverse Reactions: Hepatotoxicity is relatively common in clinical trials, necessitating monitoring of liver function. Should symptoms such as jaundice, darkening of urine, fatigue, or discomfort in the right upper abdomen occur, prompt medical attention should be sought.
Contraindications:
- Patients with a known hypersensitivity to rezvilutamide or any component of its formulation.
- Women who are pregnant or planning to conceive (see section on use in pregnant and lactating women).
Precautions:
- Liver function monitoring: Liver function should be monitored regularly during treatment, particularly during the initial phase.
- Seizures: Although the central nervous system toxicity of rezvilutamide has been reduced, physicians will exercise caution when prescribing it to patients with a history of seizures or predisposing factors.

Rezvilutamide Interactions

Effects on other medicinal products: It may reduce the plasma concentrations of certain medicinal products metabolised via hepatic cytochrome P450 enzymes (particularly CYP2C8, CYP2C9, and CYP2C19), potentially diminishing their efficacy. Close monitoring is required when used concomitantly.
Effects of other medicinal products on Rezvilutamide: Potent CYP3A4 inducers may decrease rezvilutamide plasma concentrations, affecting its efficacy. Concomitant use should be avoided.

Note:

If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.